Direct oral anticoagulants compared with vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis
CONCLUSION: DOACs and VKAs showed no difference in the safety and efficacy of patients with LVT. DOACs might be superior to VKAs for LVT treatment in post-AMI patients.PMID:35400334 | DOI:10.2174/1381612828666220408120832 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 11, 2022 Category: Drugs & Pharmacology Authors: Shu Fang Bao-Zhen Zhu Fan Yang Zhe Wang Qian Xiang Yan-Jun Gong Source Type: research

Preclinical and clinical aspects of using Tazemetostate in human cancers
Curr Pharm Des. 2022 Apr 8. doi: 10.2174/1381612828666220408121514. Online ahead of print.ABSTRACTEpigenetic drugs are novel drug categories with promising effects in different cancers. Tazemetostate is among the drugs that were recently used in clinical settings, especially in the treatment of specific tumors and lymphomas. There are a growing number of ongoing clinical trials evaluating the safety and efficacy of tazemetostate in different cancers. The present review addressed the available preclinical studies evaluating the combination of tazemetostate and other chemotherapy agents in treating different cancers and summ...
Source: Current Pharmaceutical Design - April 11, 2022 Category: Drugs & Pharmacology Authors: Leila Mousazadeh Behzad Mousazadeh Jamshid Motaei Faezeh Abbasi Reza Jafarzadeh Esfehani Source Type: research

Marine cellulases and their biotechnological significance from industrial perspectives
Curr Pharm Des. 2022 Apr 6. doi: 10.2174/1381612828666220406125132. Online ahead of print.ABSTRACTMarine microorganisms represent virtually unlimited sources of novel biological compounds, and can survive extreme conditions. Cellulases, a group of enzymes which are able to degrade cellulosic materials, are in high demand in various industrial and biotechnological applications, such as in the medical and pharmaceutical industry, food, fuel, agriculture and their applications in single cell protein and as probiotics in aquaculture. The cellulosic biopolymer is a renewable resource and is a linearly arranged polysaccharide of...
Source: Current Pharmaceutical Design - April 7, 2022 Category: Drugs & Pharmacology Authors: Azita Navvabi Ahmad Homaei Brett I Pletschke Nazila Navvabi Se-Kwon Kim Source Type: research

Marine cellulases and their biotechnological significance from industrial perspectives
Curr Pharm Des. 2022 Apr 6. doi: 10.2174/1381612828666220406125132. Online ahead of print.ABSTRACTMarine microorganisms represent virtually unlimited sources of novel biological compounds, and can survive extreme conditions. Cellulases, a group of enzymes which are able to degrade cellulosic materials, are in high demand in various industrial and biotechnological applications, such as in the medical and pharmaceutical industry, food, fuel, agriculture and their applications in single cell protein and as probiotics in aquaculture. The cellulosic biopolymer is a renewable resource and is a linearly arranged polysaccharide of...
Source: Current Pharmaceutical Design - April 7, 2022 Category: Drugs & Pharmacology Authors: Azita Navvabi Ahmad Homaei Brett I Pletschke Nazila Navvabi Se-Kwon Kim Source Type: research

Marine cellulases and their biotechnological significance from industrial perspectives
Curr Pharm Des. 2022 Apr 6. doi: 10.2174/1381612828666220406125132. Online ahead of print.ABSTRACTMarine microorganisms represent virtually unlimited sources of novel biological compounds, and can survive extreme conditions. Cellulases, a group of enzymes which are able to degrade cellulosic materials, are in high demand in various industrial and biotechnological applications, such as in the medical and pharmaceutical industry, food, fuel, agriculture and their applications in single cell protein and as probiotics in aquaculture. The cellulosic biopolymer is a renewable resource and is a linearly arranged polysaccharide of...
Source: Current Pharmaceutical Design - April 7, 2022 Category: Drugs & Pharmacology Authors: Azita Navvabi Ahmad Homaei Brett I Pletschke Nazila Navvabi Se-Kwon Kim Source Type: research

Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS
Curr Pharm Des. 2022;28(6):427. doi: 10.2174/138161282806220218141218.NO ABSTRACTPMID:35379121 | DOI:10.2174/138161282806220218141218 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 5, 2022 Category: Drugs & Pharmacology Authors: Paulus S Rommer Uwe K Zettl Source Type: research

Contemporary Management of Deep Vein Thrombosis, Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2022;28(7):511. doi: 10.2174/138161282807220221103233.NO ABSTRACTPMID:35379122 | DOI:10.2174/138161282807220221103233 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 5, 2022 Category: Drugs & Pharmacology Authors: Marios Sagris Damianos G Kokkinidis Christos Bakoyiannis Source Type: research

Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS
Curr Pharm Des. 2022;28(6):427. doi: 10.2174/138161282806220218141218.NO ABSTRACTPMID:35379121 | DOI:10.2174/138161282806220218141218 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 5, 2022 Category: Drugs & Pharmacology Authors: Paulus S Rommer Uwe K Zettl Source Type: research

Contemporary Management of Deep Vein Thrombosis, Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2022;28(7):511. doi: 10.2174/138161282807220221103233.NO ABSTRACTPMID:35379122 | DOI:10.2174/138161282807220221103233 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 5, 2022 Category: Drugs & Pharmacology Authors: Marios Sagris Damianos G Kokkinidis Christos Bakoyiannis Source Type: research

Current Pharmaceutical Trends in Neuroimmunology - Part I: Disorders Affecting the CNS
Curr Pharm Des. 2022;28(6):427. doi: 10.2174/138161282806220218141218.NO ABSTRACTPMID:35379121 | DOI:10.2174/138161282806220218141218 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 5, 2022 Category: Drugs & Pharmacology Authors: Paulus S Rommer Uwe K Zettl Source Type: research

Contemporary Management of Deep Vein Thrombosis, Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2022;28(7):511. doi: 10.2174/138161282807220221103233.NO ABSTRACTPMID:35379122 | DOI:10.2174/138161282807220221103233 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 5, 2022 Category: Drugs & Pharmacology Authors: Marios Sagris Damianos G Kokkinidis Christos Bakoyiannis Source Type: research

Applications of Nanotechnology-Based Approaches to Overcome Multi-Drug Resistance in Cancer
Curr Pharm Des. 2022 Apr 1. doi: 10.2174/1381612828666220401142300. Online ahead of print.ABSTRACTCancer is one of the leading causes of death worldwide. Chemotherapy and radiation therapy are the major treatments used for the management of cancer. Multidrug resistance (MDR) is a major hindrance faced in the treatment of cancer and is also responsible for cancer relapse. To date, several studies have been carried out on strategies to overcome or reverse MDR in cancer. Unfortunately, the MDR reversing agents have been proven to have minimal clinical benefits and eventually there is no improvement in therapeutic efficacy to ...
Source: Current Pharmaceutical Design - April 3, 2022 Category: Drugs & Pharmacology Authors: Sana Kalave Namita Hegde Kapil Juvale Source Type: research

Captopril and Spironolactone Can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33
CONCLUSION: Obtained results suggest that S+C combination therapy can improve nephropathy and diabetes disorders by targeting the ABCA1 and miR-33 gene expression. It is suggested miR-33 and ABCA1 genes evaluation could be a new therapeutic strategy for nephropathy diabetes remediation.PMID:35366766 | DOI:10.2174/1381612828666220401143249 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 3, 2022 Category: Drugs & Pharmacology Authors: Tina Ghaffari Nariman Moradi Elham Chamani Zahra Ebadi Reza Fadaei Shahin Alizadeh-Fanalou Sahar Yarahmadi Soudabeh Fallah Source Type: research

S-Allylcysteine (SAC) Exerts Renoprotective Effects via Regulation of TGF- β1/Smad3 Pathway Mediated Matrix Remodeling in Chronic Renal Failure
CONCLUSION: Furthermore, the fibrosis signaling markers mediators, such as SMAD-2,-3 were increased with associated matrix proteins. Thus, the present study substantiated that SAC possesses a significant renoprotective effect that might have been demonstrated by the inhibition of the TGF-β1/Smad3 signaling pathway.PMID:35366767 | DOI:10.2174/1381612828666220401114301 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - April 3, 2022 Category: Drugs & Pharmacology Authors: Ramkumar Samynathan Umadevi Subramanian Baskar Venkidasamy Mohammad Ali Shariati Ill-Min Chung Muthu Thiruvengadam Source Type: research

Applications of Nanotechnology-Based Approaches to Overcome Multi-Drug Resistance in Cancer
Curr Pharm Des. 2022 Apr 1. doi: 10.2174/1381612828666220401142300. Online ahead of print.ABSTRACTCancer is one of the leading causes of death worldwide. Chemotherapy and radiation therapy are the major treatments used for the management of cancer. Multidrug resistance (MDR) is a major hindrance faced in the treatment of cancer and is also responsible for cancer relapse. To date, several studies have been carried out on strategies to overcome or reverse MDR in cancer. Unfortunately, the MDR reversing agents have been proven to have minimal clinical benefits and eventually there is no improvement in therapeutic efficacy to ...
Source: Current Pharmaceutical Design - April 3, 2022 Category: Drugs & Pharmacology Authors: Sana Kalave Namita Hegde Kapil Juvale Source Type: research